Robustness of highly purified eicosapentaenoic acid trials and their cardiovascular outcomes
EPA added to statins lowers cardiovascular events, most robustly in high-risk patients with elevated triglycerides. Trial design, endpoints, and patient characteristics drive heterogeneity, while fragility analyses complement conventional metrics in interpreting outcomes.
Authors
- Marco Zuin (ORCID: https://orcid.org/0000-0002-4559-1292)
- Claudio Bilato
Institutions
- University of Padua (IT)
- University of Ferrara (IT)
- Hospital Madre Teresa (BR)
- International Renal Research Institute of Vicenza (IT)
Publication Details
- Journal
- Journal of Cardiovascular Medicine
- Published
- 2026-03-04
- DOI
- https://doi.org/10.2459/jcm.0000000000001857
- Primary Topic
- Fatty Acid Research and Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00